1 Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
2 Department of Clinical Epidemiology and Biostatistics, and Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Thyroid. 2019 Jan;29(1):64-70. doi: 10.1089/thy.2018.0554. Epub 2018 Dec 31.
Current guidelines allow lobectomy as treatment for 1-4 cm papillary thyroid carcinomas (PTCs), as previous studies reported no clear survival advantages for total thyroidectomy (TT). However, data on recurrence based on surgical extent are limited.
This study enrolled 2345 patients with 1-4 cm PTC. Those with lateral cervical lymph node metastasis or initial distant metastasis were excluded. Disease-free survival (DFS) was compared after 1:1 propensity score matching by age, sex, tumor size, extrathyroidal extension, multifocality, and cervical lymph node metastasis.
Lobectomy was performed in 383 (16.3%) and TT in 1962 (83.7%) patients. In the matched-pair analysis (381 patients in each group), no significant difference in DFS was observed during the median follow-up of 9.8 years (hazard ratio [HR] = 1.35 [confidence interval (CI) 0.40-1.36], p = 0.33). When stratified by tumor size, DFS did not differ between the group with 1-2 cm tumors and that with 2-4 cm tumors (HR = 1.57 [CI 0.75-3.25], p = 0.228; HR = 0.93 [CI 0.30-2.89], p = 0.902, respectively). Multivariate analysis showed that the surgical extent did not play an independent role in structural persistent/recurrent disease development (HR = 1.43 [CI 0.72-2.83], p = 0.306).
Patients with 1-4 cm PTCs who underwent lobectomy exhibited DFS rates similar to those who underwent TT after controlling for major prognostic factors. This supports the feasibility of lobectomy as initial surgical approach for these patients and emphasizes that tumor size should not be an absolute indication for TT.
目前的指南允许对 1-4cm 的甲状腺乳头状癌(PTC)行 lobectomy 治疗,因为此前的研究报告称全甲状腺切除术(TT)并没有明显的生存优势。然而,基于手术范围的复发数据有限。
本研究纳入了 2345 例 1-4cm 的 PTC 患者。排除了伴有侧颈淋巴结转移或初始远处转移的患者。通过年龄、性别、肿瘤大小、甲状腺外侵犯、多灶性和颈部淋巴结转移的 1:1 倾向评分匹配,比较无病生存(DFS)。
383 例(16.3%)患者行 lobectomy,1962 例(83.7%)患者行 TT。在匹配对分析(每组 381 例)中,在中位随访 9.8 年期间,DFS 无显著差异(风险比[HR]1.35 [置信区间(CI)0.40-1.36],p=0.33)。按肿瘤大小分层时,1-2cm 肿瘤组和 2-4cm 肿瘤组之间 DFS 无差异(HR 1.57 [CI 0.75-3.25],p=0.228;HR 0.93 [CI 0.30-2.89],p=0.902)。多变量分析显示,手术范围在结构性持续性/复发性疾病发展方面没有独立作用(HR 1.43 [CI 0.72-2.83],p=0.306)。
在控制主要预后因素后,行 lobectomy 的 1-4cm PTC 患者的 DFS 率与行 TT 的患者相似。这支持 lobectomy 作为此类患者初始手术方法的可行性,并强调肿瘤大小不应作为 TT 的绝对指征。